BIBX 1382

EGFR inhibitor,potent and selective CAS# 196612-93-8

BIBX 1382

Catalog No. BCC1418----Order now to get a substantial discount!

Product Name & Size Price Stock
BIBX 1382: 5mg $104 In Stock
BIBX 1382: 10mg Please Inquire In Stock
BIBX 1382: 20mg Please Inquire Please Inquire
BIBX 1382: 50mg Please Inquire Please Inquire
BIBX 1382: 100mg Please Inquire Please Inquire
BIBX 1382: 200mg Please Inquire Please Inquire
BIBX 1382: 500mg Please Inquire Please Inquire
BIBX 1382: 1000mg Please Inquire Please Inquire
Related Products
  • AG-18

    Catalog No.:BCC1051
    CAS No.:118409-57-7
  • AP26113

    Catalog No.:BCC1069
    CAS No.:1197958-12-5
  • WZ4002

    Catalog No.:BCC1074
    CAS No.:1213269-23-8
  • WZ8040

    Catalog No.:BCC1075
    CAS No.:1214265-57-2

Quality Control of BIBX 1382

Number of papers citing our products

Chemical structure

BIBX 1382

3D structure

Chemical Properties of BIBX 1382

Cas No. 196612-93-8 SDF Download SDF
PubChem ID 6918508 Appearance Powder
Formula C18H19ClFN7 M.Wt 387.84
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Falnidamol
Solubility DMSO : ≥ 41 mg/mL (105.71 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 4-N-(3-chloro-4-fluorophenyl)-6-N-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-4,6-diamine
SMILES CN1CCC(CC1)NC2=NC=C3C(=N2)C(=NC=N3)NC4=CC(=C(C=C4)F)Cl
Standard InChIKey FTFRZXFNZVCRSK-UHFFFAOYSA-N
Standard InChI InChI=1S/C18H19ClFN7/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of BIBX 1382

DescriptionBIBX 1382 is a potent, selective inhibitor of EGFR tyrosine kinase (IC50 = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 μM) and a range of other related tyrosine kinases (IC50 > 10 μM). IC50 value: 3 nM [1] Target: EGFR in vitro: BIBX1382 and BIBU1361 are both potent and selective submicromolar inhibitors of the EGFR kinase activity. An IC50 value of 3 nM was determined for both compounds. The potency of these two compounds compares with the one obtained with Iressa, which is a leading EGFR inhibitor in the field. Inhibition of the closest family member, HER2, was 100- to 1000-fold less potent. Furthermore, BIBX1382 and BIBU1361 did not inhibit a number of other related tyrosine kinases [1]. in vivo: In nude mice, oral once daily dosing at 10 mg/kg with either BIBX1382 or BIBU1361 completely suppressed tumor growth of human A431 xenografts with respective T/C values of 15 and 6% after 2 weeks of treatment [1].

References:
[1]. Solca FF, et al. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther. 2004 Nov;311(2):502-9.

BIBX 1382 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

BIBX 1382 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of BIBX 1382

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.5784 mL 12.8919 mL 25.7838 mL 51.5677 mL 64.4596 mL
5 mM 0.5157 mL 2.5784 mL 5.1568 mL 10.3135 mL 12.8919 mL
10 mM 0.2578 mL 1.2892 mL 2.5784 mL 5.1568 mL 6.446 mL
50 mM 0.0516 mL 0.2578 mL 0.5157 mL 1.0314 mL 1.2892 mL
100 mM 0.0258 mL 0.1289 mL 0.2578 mL 0.5157 mL 0.6446 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on BIBX 1382

BIBX1382 is a potent, selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase with IC50 value of 3 nM.[1]

BIBX1382 is an inhibitor of EGFR kinase for treatment of cancer. In a tyrosine kinase activity assay using cytoplasmic tyrosine kinase domains of EGFR, HER2, VEGFR2, HGFR, IGF1R, B-InsRK and c-src cloning and expressing in Sf9 insect cells, BIBX1382 selectively and potently inhibited EGFR kinase activity with an IC50 value of 3 nM. In the EGFR and pEGFR ELISA assay using EGFR highly expressed A431 cells (vuval squamous cell carcinoma), BIBX1382 inhibited EGFR phosphorylation at EC50 at 141 nM.[1] In A431, FaDu (hypopharyngeal squamous cell carcinoma) and HN5 (head and neck squamous cell carcinoma) xenograft nude mice models, oral administration of BIBX1382 at dose of 10 mg/kg daily showed strong antitumor activity in a dose-dependent manner after 2 weeks of treatment. Moreover, tumor regressions were obtained after 170 days’ long term oral administration of BIBX1382 at dose of 50 mg/kg daily in A431 xenograft nice model.[1]

References:
1. F. F. Solca, A. Baum, E. Langkopf, G. Dahmann, K. H. Heider, F. Himmelsbach and J. C. van Meel, J Pharmacol Exp Ther 2004, 311, 502-509.

Featured Products
New Products
 

References on BIBX 1382

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.[Pubmed:12008195]

Eur J Cancer. 2002 May;38(8):1072-80.

The pyrimido-pyrimidine BIBX 1382 BS inhibits the intracellular tyrosine kinase domain of the epidermal growth factor receptor (EGFR), thus specifically reverting the aberrant enzymatic activity from overexpressed and constitutively activated EGFR. A phase I and pharmacokinetic study of this new specific molecule was carried out. After initially performing an accelerated titration design from the first toxicities onwards, a modified Fibonacci scheme was used to escalate the daily oral dose. The following dosages and cycles (defined as treatment during 28 days) were applied: 25 mg: 6; 50 mg: 3; 100 mg: 6; 200 mg: 7; 150 mg: 3. Over a 10 months accrual phase, 11 patients (pts) (7 females, 4 males) with a median age of 63 years (range 50-73 years), World Health Organization Performance Status (WHO PS) 0:5 pts, 1:6 pts and miscellaneous solid tumours were entered. The median number of cycles applied per pt was 2 (range 1-7). Reversible, dose-dependent increase of liver enzymes (maximal Common Toxicity Criteria (CTC) grades: gamma-glutamyl transferase (GGT): 4, aspartate aminotransferase (GOT): 3, alanine aminotransferase (GPT): 3, alkaline phosphatase (AP): 3, bilirubin: 3) occurred. Oral medication yielded plasma levels far below those expected to be efficacious. In conclusion, target plasma levels could not be reached via the oral route at a reasonable dosage. Meanwhile, a preclinically unknown metabolite was identified from the urine of one patient. Subsequently, this metabolite was found to be abundant in patient plasma. The metabolite was demonstrated to be pharmacologically inactive. Due to a dose-limiting increase of liver enzymes, low bioavailability of BIBX 1382 BS and the detection of a pharmacologically inactive metabolite, this trial was discontinued.

Description

Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity.

Keywords:

BIBX 1382,196612-93-8,Falnidamol,Natural Products,EGFR, buy BIBX 1382 , BIBX 1382 supplier , purchase BIBX 1382 , BIBX 1382 cost , BIBX 1382 manufacturer , order BIBX 1382 , high purity BIBX 1382

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: